Optimized vaccination regimen linked to exhaustive screening approaches identifies 2 novel HLA-B7 restricted epitopes within hepatitis C virus NS3 protein. - Archive ouverte HAL Access content directly
Journal Articles Microbes and Infection Year : 2006

Optimized vaccination regimen linked to exhaustive screening approaches identifies 2 novel HLA-B7 restricted epitopes within hepatitis C virus NS3 protein.

(1, 2) , (1, 2) , (3) , (1, 2) , (4) , (1, 2) , (5) , (3, 6) , (1, 2) , (7) , (8) , (1, 2) , (1, 2)
1
2
3
4
5
6
7
8

Abstract

Broad immune responses, in particular specific for the NS3 protein and mediated by both CD8+ and CD4+T lymphocytes, are thought to play a critical role in the control of hepatitis C virus (HCV) infection. In this study, we searched for novel HLA-B*0702 NS3 restricted epitopes following an optimized NS3NS4 immunization protocol in transgenic mice expressing HLA-B*0702 molecule. Combining predicted and overlapping peptides, we identified two novel epitopes, WPA10 (aa 1111-1120) and LSP10 (aa 1153-1162), which triggered significant IFN-gamma-producing T cell frequencies and high CTL responses. Both epitopes were shown to be immunogenic when used as synthetic peptides to immunize mice. The relevance of these epitopes to humans was demonstrated, as both were able in vitro to recall specific IFN-gamma and IL10-producing cells from peripheral blood mononuclear cells of HCV infected patients. Such epitopes enlarge the pool of NS3-specific CD8+T cell epitopes available to perform immunomonitoring of HCV infection and to develop vaccines.

Dates and versions

inserm-00473470 , version 1 (15-04-2010)

Identifiers

Cite

Perrine J. Martin, Peggy Parroche, Anthony Pajot, Laurence Chatel, Caroline Barreto, et al.. Optimized vaccination regimen linked to exhaustive screening approaches identifies 2 novel HLA-B7 restricted epitopes within hepatitis C virus NS3 protein.. Microbes and Infection, 2006, 8 (9-10), pp.2432-41. ⟨10.1016/j.micinf.2006.05.006⟩. ⟨inserm-00473470⟩
183 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More